HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

rTMS in fibromyalgia: a randomized trial evaluating QoL and its brain metabolic substrate.

AbstractOBJECTIVE:
This double-blind, randomized, placebo-controlled study investigated the impact of repetitive transcranial magnetic stimulation (rTMS) on quality of life (QoL) of patients with fibromyalgia, and its possible brain metabolic substrate.
METHODS:
Thirty-eight patients were randomly assigned to receive high-frequency rTMS (n = 19) or sham stimulation (n = 19), applied to left primary motor cortex in 14 sessions over 10 weeks. Primary clinical outcomes were QoL changes at the end of week 11, measured using the Fibromyalgia Impact Questionnaire (FIQ). Secondary clinical outcomes were mental and physical QoL component measured using the 36-Item Short Form Health Survey (SF-36), but also pain, mood, and anxiety. Resting-state [(18)F]-fluorodeoxyglucose-PET metabolism was assessed at baseline, week 2, and week 11. Whole-brain voxel-based analysis was performed to study between-group metabolic changes over time.
RESULTS:
At week 11, patients of the active rTMS group had greater QoL improvement in the FIQ (p = 0.032) and in the mental component of the SF-36 (p = 0.019) than the sham stimulation group. No significant impact was found for other clinical outcomes. Compared with the sham stimulation group, patients of the active rTMS group presented an increase in right medial temporal metabolism between baseline and week 11 (p < 0.001), which was correlated with FIQ and mental component SF-36 concomitant changes (r = -0.38, p = 0.043; r = 0.51, p = 0.009, respectively). QoL improvement involved mainly affective, emotional, and social dimensions.
CONCLUSION:
Our study shows that rTMS improves QoL of patients with fibromyalgia. This improvement is associated with a concomitant increase in right limbic metabolism, arguing for a neural substrate to the impact of rTMS on emotional dimensions involved in QoL.
CLASSIFICATION OF EVIDENCE:
This study provides Class II evidence that rTMS compared with sham rTMS improves QoL in patients with fibromyalgia.
AuthorsLaurent Boyer, Alix Dousset, Philippe Roussel, Nathalie Dossetto, Serge Cammilleri, Virginie Piano, Stéphanie Khalfa, Olivier Mundler, Anne Donnet, Eric Guedj
JournalNeurology (Neurology) Vol. 82 Issue 14 Pg. 1231-8 (Apr 08 2014) ISSN: 1526-632X [Electronic] United States
PMID24670891 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Topics
  • Adult
  • Aged
  • Brain (metabolism, pathology)
  • Brain Mapping (methods)
  • Double-Blind Method
  • Female
  • Fibromyalgia (metabolism, physiopathology, therapy)
  • Humans
  • Male
  • Middle Aged
  • Quality of Life
  • Surveys and Questionnaires
  • Transcranial Magnetic Stimulation (methods)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: